v3.19.3.a.u2

Collaboration Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Research and Development [Abstract] |
Summary of Total Consolidated Net Revenues from Strategic Collaborators | The following tables summarize the effects of adopting ASC 606 on our consolidated financial statements at December 31, 2019, and for the year ended December 31, 2019 (in thousands, except per share data):
|  | As of December 31, 2019
Consolidated Balance Sheet |  | As reported under ASC 606 |  | Adjustments |  | Balance without adoption of ASC 606
Deferred revenue, current |  | $ | 63,310 |  |  | $ | (8,054 | ) |  | $ | 55,256 |
Deferred revenue, non-current |  | 138,995 |  |  | 4,012 |  |  | 143,007 |
Accumulated deficit |  | (1,496,454 | ) |  | 6,785 |  |  | (1,489,669 | )
|  | Year Ended December 31, 2019
Consolidated Statement of Operations |  | As reported under ASC 606 |  | Adjustments |  | Amount without adoption of ASC 606
Revenue: |  |  |  |  |  |
Collaboration revenue |  | $ | 42,803 |  |  | $ | 2,767 |  |  | $ | 45,570 |
Collaboration revenue from related party |  | 5,233 |  |  | 32,002 |  |  | 37,235 |
Total revenue |  | 60,209 |  |  | 34,769 |  |  | 94,978 |
Loss from operations |  | (545,720 | ) |  | 34,769 |  |  | (510,951 | )
Loss before income taxes |  | (514,716 | ) |  | 34,769 |  |  | (479,947 | )
Net loss |  | (514,021 | ) |  | 34,769 |  |  | (479,252 | )
Net loss per share - basic and diluted |  | (1.55 | ) |  | 0.10 |  |  | (1.45 | )
The cumulative effect of applying both ASC 606 and ASC 842 on our consolidated balance sheets as of January 1, 2019 was as follows (in thousands):
|  | Balance as of December 31, 2018 (1) |  | Effect of the Adoption of |  | Balance as of January 1, 2019
|  |  | ASC 842 |  | ASC 606 |
Assets: |  |
Accounts receivable |  | $ | 11,686 |  |  | $ | — |  |  | $ | (2,738 | ) |  | $ | 8,948 |
Prepaid expenses and other current assets |  | 28,399 |  |  | (300 | ) |  | — |  |  | 28,099 |
Property and equipment, net |  | 211,977 |  |  | (2,483 | ) |  | — |  |  | 209,494 |
Right-of-use assets, operating leases |  | — |  |  | 63,334 |  |  | — |  |  | 63,334 |
Total assets |  | $ | 1,962,149 |  |  | $ | 60,551 |  |  | $ | (2,738 | ) |  | $ | 2,019,962 |
Liabilities and Shareholders’ Equity: |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 109,056 |  |  | $ | — |  |  | $ | (27,281 | ) |  | $ | 81,775 |
Other current liabilities |  | 3,464 |  |  | 5,867 |  |  | — |  |  | 9,331 |
Deferred revenue, non-current |  | 165,352 |  |  | — |  |  | (3,441 | ) |  | 161,911 |
Operating lease liabilities, non-current |  | — |  |  | 64,250 |  |  | — |  |  | 64,250 |
Finance lease liabilities, non-current |  | — |  |  | 37,718 |  |  | — |  |  | 37,718 |
Deferred lease obligation, non-current |  | 10,006 |  |  | (10,006 | ) |  | — |  |  | — |
Lease financing obligation |  | 33,489 |  |  | (33,489 | ) |  | — |  |  | — |
Accumulated deficit |  | (1,006,627 | ) |  | (3,789 | ) |  | 27,984 |  |  | (982,432 | )
Total liabilities and shareholders’ equity |  | $ | 1,962,149 |  |  | $ | 60,551 |  |  | $ | (2,738 | ) |  | $ | 2,019,962 |
_______ (1) As reported in our 2018 Annual Report on Form 10-K. The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in thousands):
|  | Years Ended
Collaboration Revenue by Strategic Collaborator: |  | December 31, 2019 as reported (under ASU 606) |  | December 31, 2019 without adoption of 606 (under ASC 605) |  | December 31, 2018 as reported (under ASC 605)
Merck |  | $ | 36,608 |  |  | $ | 38,977 |  |  | $ | 66,082 |
AstraZeneca |  | 5,233 |  |  | 37,235 |  |  | 45,993 |
Vertex |  | 6,195 |  |  | 6,593 |  |  | 10,437 |
Total collaboration revenue |  | $ | 48,036 |  |  | $ | 82,805 |  |  | $ | 122,512 |
Changes in Balances of Receivables and Contract Liabilities | The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2019 (in thousands):
|  | January 1, 2019 |  | Additions |  | Deductions |  | December 31, 2019
Contract Assets: |  |  |  |  |  |  |  |
Accounts receivable |  | $ | 4,612 |  |  | $ | 11,890 |  |  | $ | (14,530 | ) |  | $ | 1,972 |
Contract Liabilities: |  |  |  |  |  |  |  |
Deferred revenue |  | $ | 240,924 |  |  | $ | 10,591 |  |  | $ | (51,987 | ) |  | $ | 199,528 |
During the year ended December 31, 2019, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):
Revenue recognized in the period from: |  |  | Year Ended December 31, 2019
Amounts included in contract liabilities at the beginning of the period (1) |  |  | $ | 51,987 |
(1) We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.10-01.(b)(6)) -URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 + Details
Name: | us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration